INSM logo

Insmed Inc

INSM

Build a strategy around INSM

Accountable AI Logo

Insmed Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-12

Snapshot

  • R&D spend of 695.9M TTM is 156% of revenue (447M) - pre-commercial biotech burning cash to advance pipeline[Research and Development TTM]
  • FCF of -906M TTM with only 335M cash remaining; 1.2B investment purchases suggest recent capital raise deployed[Free Cash Flow TTM]
  • P/S ratio of 93x vs industry median 4.1x - market pricing in massive revenue inflection from pipeline[Price to Sales Ratio]

Watch Triggers

  • Cash and Equivalents: Falls below 200M or new equity raise announcedSignals imminent dilution; current 335M insufficient for 12-month burn
  • Total Revenue TTM: Quarterly revenue exceeds 150M (600M run rate)Validates commercial traction needed to justify valuation
  • Research and Development TTM: R&D/Revenue ratio drops below 100%Indicates transition from development to commercialization phase

Bull Case

Gross margin of 77% TTM demonstrates strong unit economics; if pipeline succeeds, operating leverage is massive with 1.3B opex base already built

Gross Margin TTMOperating Expense TTM

Working capital of 1.5B provides 18+ months runway even at current burn; recent 1.2B investment activity suggests strategic deployment

Working CapitalPurchase of Investment

Bear Case

Burning 906M FCF annually with 335M cash - dilutive financing imminent; stock issuance history (-256K) shows willingness to dilute

Free Cash Flow TTMCash and Equivalents

93x P/S requires flawless execution; any pipeline setback destroys thesis given zero margin of safety at current valuation

Price to Sales RatioNet Income TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
35%

Leverage INSM's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Cash runway is critical constraint - current burn rate exhausts reserves within 6 months without financing

3-12mhigh
  • FCF burn of -906M TTM vs 335M cash
  • R&D intensity at 156% of revenue
  • Debt/equity 0.61 limits debt capacity
Cash 335M, FCF -906M TTMLong-term debt 569M already on booksRecent 1.2B investment deployment

Revenue must inflect 5-10x to justify 42B market cap given current 447M TTM revenue base

3-5ymed
  • EV/Revenue of 94x requires blockbuster
  • Gross margin 77% supports scale leverage
  • Operating loss 990M needs revenue offset
Revenue 447M, EV 42BGross margin 76.5% TTMOperating income -990M TTM

Valuation Context

Caveats

Public Strategies Rankings

See how Insmed Inc ranks across different investment strategies.

Leverage INSM's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.